课题基金 / 基金详情

NOVEL RECOMBINANT ADENOVIRUS VACCINE VECTORS FOR HIV/SIV IN RHESUS MONKEYS

NOVEL RECOMBINANT ADENOVIRUS VACCINE VECTORS FOR HIV/SIV IN RHESUS MONKEYS
用于恒河猴 HIV/SIV 的新型重组腺病毒疫苗载体
批准号：
8172824
负责人：
Dan H. Barouch
金额：
$6.58万
依托单位：
HARVARD MEDICAL SCHOOL
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
项目状态：
已结题
起止时间：
2010-05-01 至 2011-04-30
来源：
https://reporter.nih.gov/project-details/8172824
关键词：
AddressAdenovirus VectorAdenovirusesAntigensComputer Retrieval of Information on Scientific Projects DatabaseFundingGrantHIV-1HIV-1 vaccineImmuneInstitutionMacaca mulattaRecombinantsResearchResearch PersonnelResourcesSerotypingSourceUnited States National Institutes of HealthVirusnext generationnovelvectorvector vaccinevector-based vaccine

项目摘要

项目成果

Dan H. Barouch的其他基金

相似基金

相关文献

中文摘要
翻译
这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 下一代HIV-1疫苗将需要更强大的载体和抗原，以应对全球病毒多样性的挑战。因此，我们开发了基于稀有腺病毒血清型和嵌合型HIV-1抗原的新型复制不能复制的腺病毒载体疫苗，以扩大细胞免疫的广度和深度。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Next generation HIV-1 vaccines will require more potent vectors as well as antigens that address the challenge of global virus diversity. We have therefore developed novel replication-incompetent adenovirus vector-based vaccines derived from rare adenovirus serotypes as well as mosaic HIV-1 antigens to expand cellular immune breadth and depth.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NHP Core
Multi-Omics Analysis of Broadly Neutralizing Antibodies and Therapeutic Vaccination
Administrative Core
Multi-Omics Correlates of Broadly Neutralizing Antibody Efficacy
海外基金